![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Eric Lawitz,1 Fred Poordad,1 Julio Gutierrez,1 Thomas N Kakuda,2 Gaston Picchio,3
Greet Beets,4 Ann Vandevoorde,4 Pieter Van Remoortere,2 Bert Jacquemyn,4
Gemma Quinn,4 Donghan Luo,2 Sivi Ouwerkerk-Mahadevan,5 Leen Vijgen,4
Veerle Van Eygen,4 Maria Beumont5
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA;
2Janssen Research & Development LLC, Titusville, NJ, USA; 3Janssen Research & Development, San Diego, CA, USA; 4Janssen Infectious Diseases BVBA, Beerse, Belgium;
5Janssen Research & Development, Beerse, Belgium
![AASLD1.gif](../images/111615/111615-7/AASLD1.gif)
![AASLD2.gif](../images/111615/111615-7/AASLD2.gif)
![AASLD3.gif](../images/111615/111615-7/AASLD3.gif)
![AASLD4.gif](../images/111615/111615-7/AASLD4.gif)
![AASLD5.gif](../images/111615/111615-7/AASLD5.gif)
![AASLD6.gif](../images/111615/111615-7/AASLD6.gif)
![AASLD7.gif](../images/111615/111615-7/AASLD7.gif)
![AASLD8.gif](../images/111615/111615-7/AASLD8.gif)
![AASLD9.gif](../images/111615/111615-7/AASLD9.gif)
![AASLD10.gif](../images/111615/111615-7/AASLD10.gif)
![AASLD11.gif](../images/111615/111615-7/AASLD11.gif)
![AASLD12.gif](../images/111615/111615-7/AASLD12.gif)
![AASLD13.gif](../images/111615/111615-7/AASLD13.gif)
![AASLD14.gif](../images/111615/111615-7/AASLD14.gif)
![AASLD15.gif](../images/111615/111615-7/AASLD15.gif)
![AASLD16.gif](../images/111615/111615-7/AASLD16.gif)
![AASLD17.gif](../images/111615/111615-7/AASLD17.gif)
![AASLD18.gif](../images/111615/111615-7/AASLD18.gif)
![AASLD19.gif](../images/111615/111615-7/AASLD19.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|